The Latest Malaria News, in 60 Seconds.
In September 2021, the Malaria Minute was rebranded the Johns Hopkins Malaria Minute.
Listen Now or Read the Announcement
Researchers evaluate the immunogenicity of the AGS-v vaccine which targets saliva produced by Anopheles gambiae mosquitoes.
New mutations to the quinoline drug family identified in South America and Asia are not prevalent in Africa and scientists evaluate a new field-based malaria blood test.
Artefenomel is assessed against Plasmodium vivax infection in humans to determine the minimum effective dose required for parasite clearance and LSHTM launch a beta version of The Global Vector Hub.
The spleen plays a major role in the expression of P. vivax genes and the production of antigens associated with clinical protection, and scientists develop an AI that can detect Plasmodium infection in the blood.
The BioMalPar conference takes place online and the synchronisation of Plasmodium infection is controlled by the parasite’s own internal clock
Antibody tests for P. vivax malaria could reduce disease prevalence by up to 69% and scientists develop a sex-distorter gene drive that eliminates populations of mosquitoes in the lab.
Scientists find that microsporidia MB stops malaria transmission in Anopheles arabiensis mosquitoes by disrupting oocyst formation.
The combined use of mass drug administration and indoor residual spraying is the most effective way to reduce malaria prevalence in low malaria-endemic settings, and antibodies against PfGARP kill malaria-infected cells by inducing cell death.
A summary of where we are in the fight against malaria and an overview of what more needs to be done.
Genetic variation would seem to have little impact on the success of gene drive interventions due to conserved Cas9 target sites in populations of Anopheles mosquitoes.